Smith TR, Winner P, Aurora SK, Jeleva M, et al. STOP 301: A Phase 3, open-label study of safety, tolerability, and exploratory efficacy of INP104, Precision Olfactory Delivery (POD((R)) ) of dihydroergotamine mesylate, over 24/52 weeks in acute treatment of migraine attacks in adult patients. Headache 2021 Aug 7. doi: 10.1111/head.14184.
PMID: 34363701